Fidaxomicin-d7
Product Specifications
UNSPSC Description
Fidaxomicin-d7 (OPT-80-D7) is the deuterium labeled Fidaxomicin. Fidaxomicin (OPT-80), a macrocyclic RNA polymerase inhibitor, has a narrow spectrum of activity. Fidaxomicin selectively eradicates pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora[1][2].
Target Antigen
Antibiotic; Apoptosis; Bacterial; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection;Apoptosis;Others
Applications
COVID-19-immunoregulation
Field of Research
Infection
Purity
97.18
Solubility
10 mM in DMSO
Smiles
C(O[C@H]1[C@H](O)[C@H](OC)[C@H](OC/C=2/C(=O)O[C@]([C@@H](C)O)(C/C=C(\C)/C=C(\C)/[C@H](O[C@H]3[C@@H](O)[C@@H](O)[C@H](OC(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])[2H])=O)C(C)(C)O3)[C@@H](CC)/C=C(\C)/[C@@H](O)C/C=C/C2)[H])O[C@@H]1C)(=O)C4=C(CC)C(Cl)=C(O)C(Cl)=C4O
Molecular Weight
1065.08
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Poxton IR, et al. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. Future Microbiol. 2010 Apr;5(4):539-48.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Clinical Information
No Development Reported
CAS Number
2143934-06-7
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
